International Medical Journal (ISSN:13412051)

Aim and Scope

Aim-

International Medical Journal ISSN: (13412051) is an international open-access journal publishes twelve times each year. The "International Medical Journal" is a peer-reviewed, monthly, online international research journal, which publishes original articles, research articles, review articles with top-level work from all areas of Medical Science Research and their application including Aetiology, bioengineering, biomedicine, cardiology, chiropody, ENT etc. Researchers in all Medical Science and Pharmacy fields are encouraged to contribute articles based on recent research. Journal publishes research articles and reviews within the whole field of Medical Science and Pharmacy Research, and it will continue to provide information on the latest trends and developments in this ever-expanding subject. International Medical Journal journal covers almost all disciplines of Medical Science and Pharmacy. Researchers and students of M.B.B.S, M.D., D.T.C.D., GYNE., M.S., M.Pharma, And PhD are requested to send their original research articles to International Medical Journal.

Scope-

International Medical Journal ISSN: (13412051) is a peer-reviewed journal. The journal seeks to publish original research articles that are hypothetical and theoretical in its nature and that provide exploratory insights in the following fields but not limited to:

Anatomy Physiology Biochemistry Pharmacology
Pathology Forensic medicine Microbiology Community Medicine
Otorhinolaryngology Internal Medicine General Surgery Obstetrics and Gynecology
Radiology Pulmonary Medicine Dermatology and Venereal diseases Infectious Diseases
Anaesthesia Cancer research Neurosurgery Orthopedics

See More Scopes

Latest Journals
International Medical Journal
Journal ID : IMJ-31-08-2020-595
Total View : 439

Abstract : Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor and is used in the standard adjuvant chemotherapy regimens to treat metastatic colorectal cancer (CRC). It is the commonest antiangiogenesis agent to treat metastatic CRC. Venous thromboembolism, delayed wound healing, and spontaneous bowel perforation are the adverse events following bevacizumab treatment. According to the timing of Histula growth relative to operation and starting bevacizumab treatment, Histulas are possibly secondary to bevacizumab treatment rather than postoperative complications. We reported, a single uncommon case of bevacizumab related enterocutaneous Histula on 60 years old woman patient whose already been done R0 resection for left side colon cancer 2 years before. Adjuvant chemotherapy already been given 3 weeks after surgery (using FOLFOX 6 regiments). After 1 year follow up, multiple nodul liver metastase were found on Abdominal CT Scan, the treatment was continued with Hirst line anti-angiogenesis regiment (FOLFOX + Bevacizumab) for another 6 months. On the last cycle, low output enterocutaneous Histula was found from the laparotomy scar, the chemotherapy was interrupted for the last cycle. Conservative treatment was done, parenteral nutritions were started and spontaneous Histula healing could achieved after 10 days and no need for surgical intervention. A small, but significant percentage of CRC cases develop Bevacizumab-associated Histulas, which should be detected early and is managed conservatively.
Full article
International Medical Journal
Journal ID : IMJ-26-08-2020-591
Total View : 566

Abstract : During the search for treatments for COVID-19, clinical trials for testing hydroxychloroquine were interrupted by the WHO already on May 25, 2020 after publication of a paper in the magazine The Lancet [2] that stated that patients who had received hydroxychloroquine presented mortality rates of 35% due to severe cardiac arrhythmias. This paper was withdrawn thirteen days after its publication because it was questioned by 120 scientists of various nationalities [3], both as regards the data collected and as regards the method, and on June 2, 2020 also eighty Italian medical doctors sent a letter to The Lancet and to the WHO in which they criticized the scientific contents of the paper. [4] Then, on June 3, 2020, Dr. Tedros Adhanom Ghebreyesus, Director-General of the WHO, allowed restart of recruitment of patients in tests regarding hydroxychloroquine in the Solidarity trial. [5] The Recovery trial then became the principal study on which the WHO based its final decision to confirm for all drug agencies suspension of use of hydroxychloroquine for the treatment of COVID-19.
Full article
International Medical Journal
Journal ID : IMJ-26-08-2020-589
Total View : 437

Abstract : Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. In 2018, there were an estimated 228 million cases of malaria worldwide. The estimated number of malaria deaths stood at 405 000 in 2018. Children aged under 5 years are the most vulnerable group affected by malaria; in 2018, they accounted for 67% (272 000) of all malaria deaths worldwide. The WHO African Region carries a disproportionately high share of the global malaria burden. In 2018, the region was home to 93% of malaria cases and 94% of malaria deaths. Total funding for malaria control and elimination reached an estimated US$ 2.7 billion in 2018. Contributions from governments of endemic countries amounted to US$ 900 million, representing 30% of total funding. As the COVID-19 pandemic spreads rapidly around the globe, there is an urgent need to aggressively tackle the novel coronavirus while ensuring that other killer diseases, such as malaria, are not neglected. The WHO Global Malaria Program is leading a cross-partner effort to mitigate the negative impact of the coronavirus in malaria-affected countries and, where possible, contribute towards a successful COVID-19 response. The present review attempts to assess the progress gained in malaria elimination during the past few years and highlights some issues that could be important in successful malaria elimination.
Full article
International Medical Journal
Journal ID : IMJ-18-08-2020-585
Total View : 485

Abstract : The external factors of Anterior Cruciate Ligament (ACL) consist of plays where the athlete’s motion is disrupted by something else if the player was wearing a brace, the type of footwear being worn, and the playing surface itself. The purpose of the study was to evaluate players' and coaches' awareness of ACL injury. This study was a descriptive cross-sectional study. The study conducted on 91 participants (83 players and 8 coaches) from different areas of Palestine. The results showed that 48.2% of the studied players and 37.5 of coaches realized the role of sports as a risk factor of ACL injury. Also, the analysis showed that 72.3% of players and 87.5% of coaches’ participants were aware of ACL injury. The study confirmed that most players and coaches had adequate knowledge of ACL injury, and also realized that the main cause of ACL is sport activity.
Full article
International Medical Journal
Journal ID : IMJ-17-08-2020-584
Total View : 344

Abstract : The risk factor for the musculoskeletal disorder related to handheld devices will be persisted gripping, repetitive movements of the wrist, thumb, and fingers. The purpose of the study was to assess the effect of using mobile hand-held devices on the musculoskeletal system among physiotherapists. Method: This study was a descriptive cross-sectional study. The study conducted on 70 physiotherapists from Jenin city and under-graduated students of physiotherapy at Arab American University Palestine (AAUP). Results: the mean of the impact of using hand held-devices on Upper back/neck/shoulder pain was (3.39837), the impact of using hand held-devices on Upper back/neck/shoulder pain was (2.27834), the impact of using hand held-devices on Elbows/Wrist/Hand pain was (3.4), and the impact of using hand held devices on Knees/Feet pain was (1.5). Conclusion: The study confirmed that using hand held- devices had a negative effect on the upper musculoskeletal activity but the low effect on lower limbs.
Full article

Our Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates